skip to content


Issue No. 39 | September 17, 2010

News and Features

FDA Recommends New Pediatric Dosing of Valganciclovir (Valcyte)

“The U.S. Food and Drug Administration (FDA) is notifying healthcare professionals of new pediatric dosing recommendations for Valcyte (valganciclovir hydrochloride) oral tablets and oral solution. This change is being made to prevent potential valganciclovir overdosing in children with low body weight, low body surface area, and below normal serum creatinine.

“The revised dosing recommendations are being updated to include an upper limit on the calculated creatinine clearance using the modified Schwartz formula, which is used to calculate the pediatric dose of Valcyte.

“In summary, the FDA has determined that adding an upper limit of 150 mL/min/1.73 m2 to the creatinine clearance calculated using the Schwartz formula for the determination of pediatric doses can help prevent the potential for Valcyte overdosing. If the calculated pediatric dose of Valcyte exceeds 900 mg, a dose of 900 mg should be given to the child.”

More information is available:

Join AIDSinfo in Observing National HIV/AIDS and Aging Awareness Day

September 18 marks the third annual National HIV/AIDS and Aging Awareness Day. Older adults account for a significant proportion of those infected with HIV. According to the latest surveillance data from the CDC, approximately 29.3% of all people living with HIV in the United States are over 50 years old. National HIV/AIDS and Aging Awareness Day highlights the importance of preventing HIV infection in older adults and the need for greater understanding of and ability to address the challenges of aging with HIV/AIDS.

AIDSinfo has developed a specialty page for this awareness day with information and resources concerning HIV and aging.

More information is available:

NIDA 2010 Avant-Garde Award Recipient Will Examine Latent HIV Infection

“The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, announced today that Dr. Eric M. Verdin ... has been selected as the 2010 recipient of the NIDA Avant-Garde Award for HIV/AIDS Research for his proposal to study the mechanisms of latent HIV infection. … Dr. Verdin is Senior Investigator and Associate Director of the Gladstone Institute of Virology and Immunology and Professor of Medicine at the University of California, San Francisco. …

“Dr. Verdin's project aims to develop a new single cell technology to examine how HIV latency is established, maintained, and how the virus becomes reactivated, in primary human lymphoid cells. By observing the fate of the virus in single cells, Dr. Verdin hopes to be able to devise novel strategies to eliminate latent HIV infection, or to restrict the latent pool to a size that can be controlled by the immune system.”

More information is available: